1643368-58-4

Basic information

• Product Name: BMS-986142
• CAS NO: 1643368-58-4
• Molecular Weight: 572.611
• Mol File: 1643368-58-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 746.5±70.0 °C(Predicted)
• Density: 1.394±0.06 g/cm3(Predicted)
• CAS DataBase Reference: BMS-986142(CAS DataBase Reference)
• NIST Chemistry Reference: BMS-986142(1643368-58-4)
• EPA Substance Registry System: BMS-986142(1643368-58-4)

Safety Data

• Hazardous Substances Data: 1643368-58-4(Hazardous Substances Data)

Usage

General Description

BMS-986142 is a selective, orally available small molecule inhibitor of Bruton’s tyrosine kinase (BTK) being developed for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus. It works by preventing the activation of BTK, a key enzyme involved in the production of antibodies by B cells and the production of inflammatory mediators by macrophages. By targeting BTK, BMS-986142 reduces the inflammatory response and immune system activity, potentially providing relief from the symptoms of autoimmune diseases. Clinical trials have shown promising results in the reduction of disease activity and symptoms in patients with rheumatoid arthritis, and further research is being conducted to explore its potential in treating other autoimmune conditions.

Upstream product

• 33668-25-6 ethyl 3-oxocyclohexanecarboxylate 
• 1643156-20-0 ethyl 5-bromo-8-carbamoyl-6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-2-carboxylate 
• 174463-53-7 8-fluoro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 55289-36-6 3-bromo-2-methylaniline 
• 1374208-42-0 3-fluoro-4-bromo-6-aminobenzoic acid 
• 1643156-18-6 4-bromo-2-hydrazinyl-5-fluorobenzoic acid monohydrochloride 
• 930-68-7 cyclohexenone 
• 1050651-07-4 (S)-3-(prop-1-en-2-yl)cyclohexan-1-one 
• 1020717-99-0 4-bromo-5-fluoro-2-nitrobenzoic acid 

Relevant articles and documents

PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND

Disclosed is a process for preparing Compound 8: (8) comprising the step of reacting Compound of 7: (7) wherein R is C1-8 alkyl or benzyl in the presence of a base. Also disclosed are intermediates and processes for preparing the intermediates.

Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases. BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fc? receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiology of autoimmune disease. As a result, inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and rheumatoid arthritis. This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK. Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a reduction in safety liabilities. With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clinical studies.